Copyright Reports & Markets. All rights reserved.

Global Monoclonal Antibody for Multiple Myeloma

Buy now

Table of Contents

    2019-2024 Global Monoclonal Antibody for Multiple Myeloma Market Report (Status and Outlook)

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Monoclonal Antibody for Multiple Myeloma Market Size 2014-2024
        • 2.1.2 Monoclonal Antibody for Multiple Myeloma Market Size CAGR by Region
      • 2.2 Monoclonal Antibody for Multiple Myeloma Segment by Type
        • 2.2.1 Elotuzumab
        • 2.2.2 Daratumumab
        • 2.2.3 Siltuximab
        • 2.2.4 Dacetuzumab
        • 2.2.5 Rituximab
        • 2.2.6 Other
      • 2.3 Monoclonal Antibody for Multiple Myeloma Market Size by Type
        • 2.3.1 Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Type (2014-2019)
        • 2.3.2 Global Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Type (2014-2019)
      • 2.4 Monoclonal Antibody for Multiple Myeloma Segment by Application
        • 2.4.1 Hospital
        • 2.4.2 Drug Center
        • 2.4.3 Clinic
        • 2.4.4 Other
      • 2.5 Monoclonal Antibody for Multiple Myeloma Market Size by Application
        • 2.5.1 Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Application (2014-2019)
        • 2.5.2 Global Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Application (2014-2019)

      3 Global Monoclonal Antibody for Multiple Myeloma by Players

      • 3.1 Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Players
        • 3.1.1 Global Monoclonal Antibody for Multiple Myeloma Market Size by Players (2017-2019)
        • 3.1.2 Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Players (2017-2019)
      • 3.2 Global Monoclonal Antibody for Multiple Myeloma Key Players Head office and Products Offered
      • 3.3 Market Concentration Rate Analysis
        • 3.3.1 Competition Landscape Analysis
        • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
      • 3.4 New Products and Potential Entrants
      • 3.5 Mergers & Acquisitions, Expansion

      4 Monoclonal Antibody for Multiple Myeloma by Regions

      • 4.1 Monoclonal Antibody for Multiple Myeloma Market Size by Regions
      • 4.2 Americas Monoclonal Antibody for Multiple Myeloma Market Size Growth
      • 4.3 APAC Monoclonal Antibody for Multiple Myeloma Market Size Growth
      • 4.4 Europe Monoclonal Antibody for Multiple Myeloma Market Size Growth
      • 4.5 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size Growth

      5 Americas

      • 5.1 Americas Monoclonal Antibody for Multiple Myeloma Market Size by Countries
      • 5.2 Americas Monoclonal Antibody for Multiple Myeloma Market Size by Type
      • 5.3 Americas Monoclonal Antibody for Multiple Myeloma Market Size by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Monoclonal Antibody for Multiple Myeloma Market Size by Countries
      • 6.2 APAC Monoclonal Antibody for Multiple Myeloma Market Size by Type
      • 6.3 APAC Monoclonal Antibody for Multiple Myeloma Market Size by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Monoclonal Antibody for Multiple Myeloma by Countries
      • 7.2 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Type
      • 7.3 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Monoclonal Antibody for Multiple Myeloma by Countries
      • 8.2 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Type
      • 8.3 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Global Monoclonal Antibody for Multiple Myeloma Market Forecast

      • 10.1 Global Monoclonal Antibody for Multiple Myeloma Market Size Forecast (2019-2024)
      • 10.2 Global Monoclonal Antibody for Multiple Myeloma Forecast by Regions
        • 10.2.1 Global Monoclonal Antibody for Multiple Myeloma Forecast by Regions (2019-2024)
        • 10.2.2 Americas Market Forecast
        • 10.2.3 APAC Market Forecast
        • 10.2.4 Europe Market Forecast
        • 10.2.5 Middle East & Africa Market Forecast
      • 10.3 Americas Forecast by Countries
        • 10.3.1 United States Market Forecast
        • 10.3.2 Canada Market Forecast
        • 10.3.3 Mexico Market Forecast
        • 10.3.4 Brazil Market Forecast
      • 10.4 APAC Forecast by Countries
        • 10.4.1 China Market Forecast
        • 10.4.2 Japan Market Forecast
        • 10.4.3 Korea Market Forecast
        • 10.4.4 Southeast Asia Market Forecast
        • 10.4.5 India Market Forecast
        • 10.4.6 Australia Market Forecast
      • 10.5 Europe Forecast by Countries
        • 10.5.1 Germany Market Forecast
        • 10.5.2 France Market Forecast
        • 10.5.3 UK Market Forecast
        • 10.5.4 Italy Market Forecast
        • 10.5.5 Russia Market Forecast
        • 10.5.6 Spain Market Forecast
      • 10.6 Middle East & Africa Forecast by Countries
        • 10.6.1 Egypt Market Forecast
        • 10.6.2 South Africa Market Forecast
        • 10.6.3 Israel Market Forecast
        • 10.6.4 Turkey Market Forecast
        • 10.6.5 GCC Countries Market Forecast
      • 10.7 Global Monoclonal Antibody for Multiple Myeloma Forecast by Type
      • 10.8 Global Monoclonal Antibody for Multiple Myeloma Forecast by Application

      11 Key Players Analysis

      • 11.1 Bristol Myers Squibb
        • 11.1.1 Company Details
        • 11.1.2 Monoclonal Antibody for Multiple Myeloma Product Offered
        • 11.1.3 Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
        • 11.1.4 Main Business Overview
        • 11.1.5 Bristol Myers Squibb News
      • 11.2 Abbvie
        • 11.2.1 Company Details
        • 11.2.2 Monoclonal Antibody for Multiple Myeloma Product Offered
        • 11.2.3 Abbvie Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
        • 11.2.4 Main Business Overview
        • 11.2.5 Abbvie News
      • 11.3 Janssen Biotech
        • 11.3.1 Company Details
        • 11.3.2 Monoclonal Antibody for Multiple Myeloma Product Offered
        • 11.3.3 Janssen Biotech Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
        • 11.3.4 Main Business Overview
        • 11.3.5 Janssen Biotech News
      • 11.4 Karyopharm Therapeutics
        • 11.4.1 Company Details
        • 11.4.2 Monoclonal Antibody for Multiple Myeloma Product Offered
        • 11.4.3 Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
        • 11.4.4 Main Business Overview
        • 11.4.5 Karyopharm Therapeutics News
      • 11.5 PDL BioPharma
        • 11.5.1 Company Details
        • 11.5.2 Monoclonal Antibody for Multiple Myeloma Product Offered
        • 11.5.3 PDL BioPharma Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
        • 11.5.4 Main Business Overview
        • 11.5.5 PDL BioPharma News
      • 11.6 Roche
        • 11.6.1 Company Details
        • 11.6.2 Monoclonal Antibody for Multiple Myeloma Product Offered
        • 11.6.3 Roche Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
        • 11.6.4 Main Business Overview
        • 11.6.5 Roche News
      • 11.7 Seattle Genetics
        • 11.7.1 Company Details
        • 11.7.2 Monoclonal Antibody for Multiple Myeloma Product Offered
        • 11.7.3 Seattle Genetics Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
        • 11.7.4 Main Business Overview
        • 11.7.5 Seattle Genetics News

      ...

        12 Research Findings and Conclusion

        According to this study, over the next five years the Monoclonal Antibody for Multiple Myeloma market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Monoclonal Antibody for Multiple Myeloma business, shared in Chapter 3.

        This report presents a comprehensive overview, market shares and growth opportunities of Monoclonal Antibody for Multiple Myeloma market by product type, application, key companies and key regions.

        This study considers the Monoclonal Antibody for Multiple Myeloma value generated from the sales of the following segments:

        Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
        Elotuzumab
        Daratumumab
        Dacetuzumab
        Rituximab
        Other
        Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
        Hospital
        Drug Center
        Clinic
        Other

        This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
        Americas
        United States
        Canada
        Mexico
        Brazil
        APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
        Europe
        Germany
        France
        UK
        Italy
        Russia
        Spain
        Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

        The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
        Bristol Myers Squibb
        Abbvie
        Janssen Biotech
        Karyopharm Therapeutics
        PDL BioPharma
        Roche
        Seattle Genetics
        ...

        In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

        Research objectives
        To study and analyze the global Monoclonal Antibody for Multiple Myeloma market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
        To understand the structure of Monoclonal Antibody for Multiple Myeloma market by identifying its various subsegments.
        Focuses on the key global Monoclonal Antibody for Multiple Myeloma players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
        To analyze the Monoclonal Antibody for Multiple Myeloma with respect to individual growth trends, future prospects, and their contribution to the total market.
        To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
        To project the size of Monoclonal Antibody for Multiple Myeloma submarkets, with respect to key regions (along with their respective key countries).
        To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
        To strategically profile the key players and comprehensively analyze their growth strategies.

        Buy now